文献速递慢性肾脏病遗传性与小管间质肾病

用于常染色体显性多囊肾病试验富集的药物开发工具

A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease.
PubMed 文献 · Kidney Int Rep · 2017-02-21

该研究基于数十年观察数据,将纵向总肾脏体积(TKV)测量与估算肾小球滤过率(eGFR)下降30%或终末期肾病的概率关联,开发药物开发工具。在641例和866例常染色体显性多囊肾病患者中分别分析eGFR下降和终末期肾病。结果显示预测TKV与结局关联显著(P<0.0001),基线TKV≥1000 ml患者风险斜率更陡,提示TKV可用于试验富集。

要点

  • 纵向TKV测量可预测eGFR下降30%或终末期肾病风险。
  • 基线TKV≥1000 ml患者在不同年龄和eGFR亚组中风险更高。
  • eGFR和年龄在早期疾病中对进展预测价值有限。

核心结论

  • 当eGFR保留时,较大TKV患者更可能在临床试验期间进展至eGFR下降30%。

研究设计与样本

  • 基于数十年观察数据开发药物开发工具,eGFR下降和终末期肾病分析分别纳入641例和866例常染色体显性多囊肾病患者。

主要发现

  • 预测TKV与eGFR下降30%时及终末期肾病时的统计关联均高度显著(P < 0.0001)。
  • 基线TKV≥1000 ml患者风险斜率更陡,在各基线年龄(<或≥40岁)或基线eGFR(<或≥50 ml/min per 1.73 m2)亚组中eGFR下降30%风险更高。

关键数值与推荐

  • 基线TKV≥1000 ml与更高风险相关;基线年龄<或≥40岁、基线eGFR<或≥50 ml/min per 1.73 m2为预设亚组。

临床怎么用

  • 鼓励制药申办方和学术研究者前瞻性使用该工具优化常染色体显性多囊肾病患者的试验设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Total kidney volume (TKV) is a promising imaging biomarker for tracking and predicting the natural history of patients with autosomal dominant polycystic kidney disease. METHODS: A drug development tool was developed by linking longitudinal TKV measurements to the probability of a 30% decline of estimated glomerular filtration rate (eGFR) or end-stage renal disease. Drug development tools were developed based on observational data collected over multiple decades for an eGFR decline and end-stage renal disease in 641 and 866 patients with autosomal dominant polycystic kidney disease, respectively. RESULTS: The statistical association between predicted TKV at the time of a 30% decline of eGFR and that at the time of end-stage renal disease were both highly significant (P < 0.0001). The drug development tool was applied to demonstrate the utility of trial enrichment according to prespecified baseline TKV, age, and eGFR as enrollment criteria in hypothetical clinical trials. Patients with larger TKV (≥1000 ml) displayed steeper slopes of hazard, which translated into a higher risk of a 30% decline of eGFR within each baseline age (< or ≥40 years) or baseline eGFR (< or ≥50 ml/min per 1.73 m2) subgroups. DISCUSSION: These results suggest that, when eGFR is preserved, patients with larger TKV are more likely to progress to a 30% decline of eGFR within the course of a clinical trial, whereas eGFR and age displayed limited predictive value of disease progression in early disease. Pharmaceutical sponsors and academic investigators are encouraged to prospectively employ the above drug development tool to optimize trial designs in patients with autosomal dominant polycystic kidney disease.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Perrone RD, Mouksassi MS, Romero K, et al. A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2017. PMID: 29142972. doi:10.1016/j.ekir.2017.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。